Nonmyeloablative stem cell transplantation in follicular B-cell lymphoma

Current Hematologic Malignancy Reports

Volumn 2, Issue 4, 2007, Pages 225-231

  Tam, Constantine S ^b   Khouri, Issa ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; FLUDARABINE; MELPHALAN; METHOTREXATE; MONOCLONAL ANTIBODY; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

CANCER CENTER; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; DONOR; DONOR LYMPHOCYTE INFUSION; DRUG DOSE ESCALATION; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; MORTALITY; NONHUMAN; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; REVIEW; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; GRAFT VS TUMOR EFFECT; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; LYMPHOCYTE TRANSFUSION; LYMPHOMA, FOLLICULAR; MELPHALAN; METHOTREXATE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; STEM CELL TRANSPLANTATION; TISSUE DONORS; TRANSPLANTATION CONDITIONING; VIDARABINE;

EID: 38349081435     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-007-0031-1     Document Type: Review

References (37)

1. Horning SJ: Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993, 20:75-88.
2. Zinzani PL, Pulsoni A, Perrotti A, et al.: Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004, 22:2654-2661.
3. McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-2833.
4. Kaminski MS, Tuck M, Estes J, et al.: 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005, 352:441-449.
5. Van Besien K, Loberiza FRJ, Bajorunaite R, et al.: Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003, 102:3521-3529.
6. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al.: An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003, 31:667-678.
7. Hosing C, Saliba RM, McLaughlin P, et al.: Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. Ann Oncol 2003, 14:737-744.
8. Toze CL, Barnett MJ, Connors JM, et al.: Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation. Br J Haematol 2004, 127:311-321.
9. Bierman PJ, Sweetenham JW, Loberiza FRJ, et al.: Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation - The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 2003, 21:3744-3753.
10. Van Besien KW, de Lima M, Giralt SA, et al.: Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 1997, 19:977-982.
11. Mandigers CM, Verdonck LF, Meijerink JP, et al.: Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant 2003, 32:1159-1163.
12. Khouri IF, Keating M, Korbling M, et al.: Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998, 16:2817-2824.
13. Khouri IF, Saliba RM, Giralt SA, et al.: Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001, 98:3595-3599.
14. Khouri IF, Lee MS, Saliba RM, et al.: Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 2004, 32:28-35.
15. Khouri IF, Saliba RM, Hosing CM, et al.: Autologous stem cell (AUTO) vs non-myeloablative allogeneic transplantation (NMT) after high-dose rituximab (HD-R)-containing conditioning regimens for relapsed chemosensitive follicular lymphoma (FL) [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 48. Results of the updated M.D. Anderson experience with nonmyeloablative stem cell transplantation in follicular lymphoma.
16. Khouri IF, Lee MS, Saliba RM, et al.: Non-myeloablative allogeneic transplantation (NMT) with T-cell replete graft for relapsed chemosensitive follicular lymphoma (FL): Donor lymphocyte infusion (DLI) to convert stable mixed chimerism to full donor chimerism is not necessary in the absence of disease progression [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 3659.
17. Demidem A, Lam T, Alas S, et al.: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B-cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997, 12:177-186.
18. Alas S, Bonavida B: Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001, 61:5137-5144.
19. Di Gaetano N, Xiao Y, Erba E, et al.: Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001, 114:800-809.
20. Maloney DG, Grillo-Lopez AJ, White CA, et al.: IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90:2188-2195.
21. Hsu FJ, Komarovskaya M: CTLA4 blockade maximizes antitumor T-cell activation by dendritic cells presenting idiotype protein or opsonized anti-CD20 antibody-coated lymphoma cells. J Immunother (1997) 2002, 25:455-468.
22. Schultz KR, Paquet J, Bader S, HayGlass KT: Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant 1995, 16:289-295.
23. O'Brien SM, Kantarjian H, Thomas DA, et al.: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001, 19:2165-2170.
24. Byrd JC, Murphy T, Howard RS, et al.: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001, 19:2153-2164.
25. Kusumi E, Kami M, Kanda Y, et al.: Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan. Bone Marrow Transplant 2005, 36:205-213.
26. Vigouroux S, Michallet M, Porcher R, et al.: Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica 2007, 92:627-634.
27. Faulkner RD, Craddock C, Byrne JL, et al.: BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 2004, 103:428-434.
28. Rodriguez R, Nademanee A, Ruel N, et al.: Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006, 12:1326-1334.
29. Van Besien K, Carreras J, Zhang MJ, et al.: Reduced intensity vs myeloablative conditioning for HLA matched sibling transplantation in follicular lymphoma [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 656. International Bone Marrow Transplant Registry (IBMTR) report on NST versus myeloablative SCT for follicular lymphoma.
30. Robinson SP, Goldstone AH, Mackinnon S, et al.: Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002, 100:4310-4316.
31. Morris E, Thomson K, Craddock C, et al.: Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004, 104:3865-3871.
32. Lundin J, Porwit-MacDonald A, Rossmann ED, et al.: Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004, 18:484-490.
33. Maris MB, Sandmaier BM, Storer B, et al.: Allogeneic hematopoietic cell transplantation (HCT) after non-myeloablative conditioning for relapsed or refractory follicular lymphoma [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 1130.
34. Branson K, Chopra R, Kottaridis PD, et al.: Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 2002, 20:4022-4031.
35. Escalon MP, Champlin RE, Saliba RM, et al.: Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 2004, 22:2419-2423.
36. Khouri IF, Saliba RM, Hosing C, et al.: Efficacy and safety of yttrium 90 (90Y) ibritumomab tiuxetan in autologous and nonmyeloablative stem cell transplantation (NST) for relapsed non-Hodgkin's lymphoma (NHL) [abstract]. Blood (ASH Annual Meeting Abstracts) 2006, 108:Abstract 315.
37. Baron F, Maris MB, Sandmaier BM, et al.: Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005, 23:1993-2003.